Dengue shock

Journal of Emergencies, Trauma and Shock

Volumn 4, Issue 1, 2011, Pages 120-127

  Rajapakse, Senaka ^a  

^a UNIVERSITY OF COLOMBO   (Sri Lanka)

Author keywords

corticosteroids; Dengue; DHF; DSS; fluids; myocarditis; shock

Indexed keywords

EID: 79952384726     PISSN: 09742700     EISSN: 0974519X     Source Type: Journal    
DOI: 10.4103/0974-2700.76835     Document Type: Article

References (79)

1. nd Edition. World Health Organization; 1997.
2. Halstead SB. Dengue. Lancet 2007;370:1644-52. (Pubitemid 350052290)
3. Halstead SB. Is there an inapparent dengue explosion? Lancet 1999;353:1100-1
4. Kurane I. Dengue hemorrhagic fever with special emphasis on immunopathogenesis. Comp Immunol Microbiol Infect Dis 2007;30:329-40. (Pubitemid 47450087)
5. Littaua R, Kurane I, Ennis FA. Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol 1990;144:3183-6. (Pubitemid 20149498)
6. Mady BJ, Erbe DV, Kurane I, Fanger M W, Ennis FA. Antibody-dependent enhancement of dengue virus infection mediated by bispecific antibodies against cell surface molecules other than Fc gamma receptors. Antibodydependent enhancement of dengue virus infection mediated by bispecific antibodies against cell surface molecules other than Fc gamma receptors. 1991;147:3139-44.
7. Halstead SB, Venkateshan CN, Gentry MK, Larsen LK. Heterogeneity of infection enhancement of dengue 2 strains by monoclonal antibodies. J Immunol 1984;132:1529-32. (Pubitemid 14156077)
8. Morens DM. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 1994;19:500-12. (Pubitemid 24286955)
9. Basu A, Chaturvedi UC. Vascular endothelium: the battlefield of dengue viruses. FEMS Immunol Med Microbiol 2008;53:287-99.
10. Chaturvedi UC, Agarwal R, Elbishbishi EA, Mustafa AS. Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis. FEMS Immunol Med Microbiol 2000;28:183-8. (Pubitemid 32939398)
11. Kurane I, Ennis FE. Immunity and immunopathology in dengue virus infections. Semin Immunol 1992;4:121-7.
12. Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006;19:429-36. (Pubitemid 44338101)
13. Anderson R, Wang S, Osiowy C, Issekutz AC. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. J Virol 1997;71:4226-32. (Pubitemid 27204108)
14. King CA, Anderson R, Marshall JS. Dengue virus selectively induces human mast cell chemokine production. J Virol 2002;76:8408-19. (Pubitemid 34809093)
15. Kurane I, Meager A, Ennis FA. Induction of interferon alpha and gamma from human lymphocytes by dengue virus-infected cells. J Gen Virol 1986;67:1653-61. (Pubitemid 16077687)
16. Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Ennis FA. High levels of interferon alpha in the sera of children with dengue virus infection. Am J Trop Med Hyg 1993;48:222-9. (Pubitemid 23083739)
17. Vitarana T, de Silva H, Withana N, Gunasekera C. Elevated tumour necrosis factor in dengue fever and dengue haemorrhagic fever. Ceylon Med J 1991;36:63-5.
18. Juffrie M, Meer GM, Hack CE, Haasnoot K, Sutaryo, Veerman AJ, et al. Inflammatory mediators in dengue virus infection in children: interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2. Am J Trop Med Hyg 2001;65:70-5. (Pubitemid 32730368)
19. Huang YH, Lei HY, Liu HS, Lin YS, Liu CC, Yeh TM. Dengue virus infects human endothelial cells and induces IL-6 and IL-8 production. Am J Trop Med Hyg 2000;63:71-5.
20. Mustafa AS, Elbishbishi EA, Agarwal R, Chaturvedi UC. Elevated levels of interleukin-13 and IL-18 in patients with dengue hemorrhagic fever. FEMS Immunol Med Microbiol 2001;30:229-33. (Pubitemid 32373298)
21. Raghupathy R, Chaturvedi UC, Al-Sayer H, Elbishbishi EA, Agarwal R, Nagar R, et al. Elevated levels of IL-8 in dengue hemorrhagic fever. J Med Virol 1998;56:280-5. (Pubitemid 28458099)
22. Malasit P. Complement and dengue haemorrhagic fever/shock syndrome. Southeast Asian J Trop Med Public Health 1987;18:316-20.
23. Avirutnan P, Malasit P, Seliger B, Bhakdi S, Husmann M. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J Immunol 1998;161:6338-46. (Pubitemid 28536010)
24. Sarasombath S, Suvatte V, Homchampa P. Kinetics of lymphocyte subpopulations in dengue hemorrhagic fever/dengue shock syndrome. Southeast Asian J Trop Med Public Health 1988;19:649-56
25. Narayanan M, Aravind MA, Thilothammal N, Prema R, Sargunam CS, Ramamurty N. Dengue fever epidemic in Chennai-a study of clinical profile and outcome. Indian Pediatr 2002;39:1027-33.
26. uzmán MG, Alvarez M, Rodríguez R, Rosario D, Vázquez S, Vald s L, et al. Fatal dengue hemorrhagic fever in Cuba, 1997. Int J Infect Dis 1999;3:130-5.
27. Wu KL, Changchien CS, Kuo CM, Chuah SK, Lu SN, Eng HL, et al. Dengue fever with acute acalculous cholecystitis. Am J Trop Med Hyg 2003;68:657-60.
28. Wali JP, Biswas A, Chandra S, Malhotra A, Aggarwal P, Handa R, et al. Cardiac involvement in Dengue Haemorrhagic Fever. Int J Cardiol 1998;64:31-6. (Pubitemid 28161136)
29. Kabra SK, Juneja R, Madhulika, Jain Y, Singhal T, Dar L, et al. Myocardial dysfunction in children with dengue haemorrhagic fever. Natl Med J India 1998;11:59-61. (Pubitemid 128549448)
30. Khongphatthanayothin A, Lertsapcharoen P, Supachokchaiwattana P, La-Orkhun V, Khumtonvong A, Boonlarptaveechoke C, et al. Myocardial depression in dengue hemorrhagic fever: prevalence and clinical description. Pediatr Crit Care Med 2007;8:524-9. (Pubitemid 350076457)
31. Nimmannitya S, Thisyakorn U, Hemsrichart V. Dengue haemorrhagic fever with unusual manifestations. Southeast Asian J Trop Med Public Health 1987;18:398-406.
32. Kuo MC, Lu PL, Chang JM, Lin MY, Tsai JJ, Chen YH, et al. Impact of renal failure on the outcome of dengue viral infection. Clin J Am Soc Nephrol 2008;3:1350-6.
33. Guzmán MG, Kouri G, Bravo J, Valdes L, Vazquez S, Halstead SB. et al. Effect of age on outcome of secondary dengue 2 infections. Int J Infect Dis 2002;6:118-24. (Pubitemid 34793060)
34. Guzmán MG, Kourí G. Dengue: an update. Lancet Infect Dis 2002;2:33-42. (Pubitemid 36109304)
35. Malavige GN, Velathanthiri VG, Wijewickrama ES, Fernando S, Jayaratne SD, Aaskov J, et al. Patterns of disease among adults hospitalized with dengue infections. QJM 2006;99:299-305.
36. Kabra SK, Jain Y, Pandey RM, Madhulika, Singhal T, Tripathi P, et al. Dengue haemorrhagic fever in children in the 1996 Delhi epidemic. Trans R Soc Trop Med Hyg 1999;93:294-8. (Pubitemid 29348824)
37. Bravo JR, Guzmán MG, Kouri GP. Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Trans R Soc Trop Med Hyg 1987;81:816-20.
38. Cunha RV, Schatzmayr HG, Miagostovich MP, Barbosa AM, Paiva FG, Miranda RM, et al. Dengue epidemic in the State of Rio Grande do Norte, Brazil, in 1997. Trans R Soc Trop Med Hyg 1999;93:247-9. (Pubitemid 29348812)
39. Thisyakorn U, Nimmannitya S. Nutritional status of children with dengue hemorrhagic fever. Clin Infect Dis 1993;16:295-7. (Pubitemid 23047434)
40. Guzmán MG, Kouri GP, Bravo J, Soler M, Vazquez S, Morier L. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 1990;42:179-84. (Pubitemid 20093452)
41. Halstead SB, Streit TG, Lafontant JG, Putvatana R, Russell K, Sun W, et al. Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am J Trop Med Hyg 2001;65:180-3. (Pubitemid 32847807)
42. Loke H, Bethell DB, Phuong CX, Dung M, Schneider J, White NJ, et al. Strong HLA class I-restricted T cell responses in dengue hemorrhagic fever: a double-edged sword? J Infect Dis 2001;184:1369-73. (Pubitemid 33108849)
43. Guzmán MG, Kourí G. Dengue diagnosis, advances and challenges. Int J Infect Dis 2004;8:69-80. (Pubitemid 38166073)
44. Guzman MG, Kouri G, Soler M, Bravo J, Rodríguez de La Vega A, Vazquez S, et al. Dengue 2 virus enhancement in asthmatic and non asthmatic individual. Mem Inst Oswaldo Cruz 1992;87:559-564.
45. Cordeiro MT, Braga-Neto U, Nogueira RM, Marques ET Jr. Reliable classifier to differentiate primary and secondary acute dengue infection based on IgG ELISA. PLoS One 2009;4:4945.
46. Nawa M, Ichikawa Y, Inouye S. Serotyping of dengue viruses by an enzymelinked immunosorbent assay. Jpn J Med Sci Biol 1985;38:217-21. (Pubitemid 16132098)
47. De Paula SO, Fonseca BA. Dengue: a review of the laboratory tests a clinician must know to achieve a correct diagnosis. Braz J Infect Dis 2004;8:390-8.
48. Méndez A, González G. Dengue haemorrhagic fever in children: ten years of clinical experience. Biomedica 2003;23:180-93
49. Dung NM, Day NP, Tam DT, Loan HT, Chau HT, Minh LN, et al. Fluid replacement in dengue shock syndrome: a randomized, doubleblind comparison of four intravenous-fluid regimens. Clin Infect Dis 1999;29:787-94. (Pubitemid 30256368)
50. Ngo NT, Cao XT, Kneen R, Wills B, Nguyen VM, Nguyen TQ, et al. Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin Infect Dis 2001;32:204-13. (Pubitemid 32524789)
51. Wills BA, Nguyen MD, Ha TL, Dong TH, Tran TN, Le TT, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 2005;353:877-89. (Pubitemid 41247927)
52. Isarangkura P, Tuchinda S. The behavior of transfused platelets in dengue hemorrhagic fever. Southeast Asian J Trop Med Public Health 1993;24:222-4.
53. Sellahewa KH, Samaraweera N, Thusita KP, Fernando JL. Is fresh frozen plasma effective for thrombocytopenia in adults with dengue fever? A prospective randomised double blind controlled study. Ceylon Med J 2008;53:36-40.
54. Medin CL, Rothman AL. Cell type-specific mechanisms of interleukin-8 induction by dengue virus and differential response to drug treatment. J Infect Dis 2006;193:1070-7.
55. Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAM 1998;280:159-65. (Pubitemid 28498389)
56. Min M, U T, Aye M, Shwe TN, Swe T. et al. Hydrocortisone in the management of dengue shock syndrome. Southeast Asian J Trop Med Public Health 1975;6:573-9.
57. Futrakul P, Vasanauthana S, Poshyachinda M, Mitrakul C, Cherdboonchart V, Kanthirat V. Pulse therapy in severe form of dengue shock syndrome. J Med Assoc Thai 1981;64:485-91.
58. Sumarmo, Talogo W, Asrin A, Isnuhandojo B, Sahudi A. Failure of hydrocortisone to affect outcome in dengue shock syndrome. Pediatrics 1982;69:45-9. (Pubitemid 12209667)
59. Futrakul P, Poshyachinda M, Mitrakul C, Kwakpetoon S, Unchumchoke P, Teranaparin C, et al. Hemodynamic response to high-dose methyl prednisolone and mannitol in severe dengue-shock patients unresponsive to fluid replacement. Southeast Asian J Trop Med Public Health 1987;18:373-9. (Pubitemid 18031388)
60. Pongpanich B, Bhanchet P, Phanichyakarn P, Valyasevi A. Studies on dengue hemorrhagic fever. Clinical study: an evaluation of steroids as a treatment. J Med Assoc Thai 1973;56:6-14
61. Tassniyom S, Vasanawathana S, Chirawatkul A, Rojanasuphot S. Failure of high-dose methylprednisolone in established dengue shock syndrome: a placebo-controlled, double-blind study. Pediatrics 1993;92:111-5. (Pubitemid 23188877)
62. Sumarmo. The role of steroids in dengue shock syndrome. Southeast Asian J Trop Med Public Health 1987;18:383-9.
63. Rajapakse S. Corticosteroids in the treatment of dengue illness. Trans R Soc Trop Med Hyg 2009;103:122-6.
64. Panpanich R, Sornchai P, Kanjanaratanakorn K. Corticosteroids for treating dengue shock syndrome. Cochrane Database Syst Rev 2006;3:CD003488.
65. Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009;301:2362-75.
66. Annane D, Sébille V, Troché G, Raphaël JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;283:1038-45. (Pubitemid 30112218)
67. Myo-Khin, Soe-Thein, Thein-Thein-Myint, Than-Nu-Swe, Tin-Tin-Saw, Muya-Than. Serum cortisol levels in children with dengue haemorrhagic fever. J Trop Pediatr 1995;41:295-7.
68. Kularatne SA. Survey on the management of dengue infection in Sri Lanka: opinions of physicians and pediatricians. Southeast Asian J Trop Med Public Health 2005;36:1198-200.
69. Sibéril S, Elluru S, Negi VS, Ephrem A, Misra N, Delignat S, et al. Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies. Transfus Apher Sci 2007;37:103-7. (Pubitemid 47576779)
70. Andersson U, Björk L, Skansén-Saphir U, Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994;139:21-42. (Pubitemid 24232670)
71. El-Nawawy A, El-Kinany H, Hamdy El-Sayed M, Boshra N. Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit. J Trop Pediatr 2005;51:271-8. (Pubitemid 41508688)
72. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007;12:2686-92. (Pubitemid 350175762)
73. Ostronoff M, Ostronoff F, Florêncio R, Florêncio M, Domingues MC, Calixto R, et al. Serious thrombocytopenia due to dengue hemorrhagic fever treated with high dosages of immunoglobulin. Clin Infect Dis 2003;36:1623-4. (Pubitemid 36783350)
74. Dimaano EM, Saito M, Honda S, Miranda EA, Alonzo MT, Valerio MD, et al. Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection. Am J Trop Med Hyg 2007;77:1135-8. (Pubitemid 351837807)
75. Alejandria M. Dengue fever. Clin Evid 2005:887-95.
76. Rajapakse S. Intravenous immunoglobulins in the treatment of dengue illness. Trans R Soc Trop Med Hyg 2009;103:867-70.
77. Sendo T, Itoh Y, Aki K, Oka M, Oishi R. Carbazochrome sodium sulfonate (AC-17) reverses endothelial barrier dysfunction through inhibition of phosphatidylinositol hydrolysis in cultured porcine endothelial cells. Naunyn Schmiedebergs Arch Pharmacol 2003;368:175-80. (Pubitemid 37255478)
78. Tassniyom S, Vasanawathana S, Dhiensiri T, Nisalak A, Chirawatkul A. Failure of carbazochrome sodium sulfonate (AC-17) to prevent dengue vascular permeability or shock: a randomized, controlled trial. J Pediatr 1997;131:525-8. (Pubitemid 28006922)
79. Cam BV, Tuan DT, Fonsmark L, Poulsen A, Tien NM, Tuan HM, Heegaard ED. Randomized comparison of oxygen mask treatment vs. nasal continuous positive airway pressure in dengue shock syndrome with acute respiratory failure. J Trop Pediatr 2002;48:335-9. (Pubitemid 36024533)